This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Other Hyperphenylalaninaemias / Tetrahydrobiopterin [BH4] deficiency / Non-PKU HPA기타 고페닐알라닌혈증 (테트라하이드로바이오프테린 결핍증)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: E70.1 (other hyperphenylalaninemias) | OMIM: 261640 (PTPS), 261630 (DHPR), 233910 (GTPCH), etc. | Special Copayment Reduction: V117 (rare disease, 10% copayment for 5 years after registration)
B. SynonymsTetrahydrobiopterin deficiency (BH4 deficiency), non-PKU hyperphenylalaninemia (Non-PKU HPA), BH4-responsive HPA, malignant hyperphenylalaninemia, pterin metabolism disorder, GTPCH deficiency, PTPS deficiency, DHPR deficiency, PCD deficiency, SR deficiency
C. Adult onsetLikelihood of first presentation in adulthood: very low — most cases are detected by newborn screening, and without early treatment severe neurological symptoms progress from infancy; the autosomal dominant form of GTPCH deficiency (Segawa disease) may present with dystonia in childhood to adolescence.
1. History1970s reports of cases positive on PKU screening but with normal PAH → 1974 Smith et al. describe 'Malignant HPA' → 1970s–80s identification of BH4 biosynthetic enzymes → 1980s–90s identification of molecular genetic causes → 2020 publication of international consensus guidelines for diagnosis and treatment.
2. CausesEnzyme deficiency in the BH4 biosynthetic pathway (GTP → BH4) or the BH4 regeneration pathway. Enzymes involved: GTP cyclohydrolase I (GTPCH/GCH1), 6-pyruvoyl-tetrahydropterin synthase (PTPS), dihydropteridine reductase (DHPR/QDPR), pterin-4a-carbinolamine dehydratase (PCD), sepiapterin reductase (SR). BH4 is a cofactor of PAH, TH, and TPH.
3. GeneticsMostly autosomal recessive (HPA form of GTPCH deficiency, PTPS, DHPR, PCD, SR). Segawa syndrome due to GTPCH deficiency is autosomal dominant (AD). Genes involved: GCH1 (14q22.1), PTS (11q23.1), QDPR (4p15.32), PCBD1 (10q22.1), SPR (2p13.2). PTPS deficiency is the most common in Asia.
4. General epidemiologyAccounts for about 1–3% of all HPA. Worldwide incidence of BH4 deficiency about 1:1,000,000–1:2,000,000. In East Asia, including Korea and China, PTPS deficiency is the most common form of BH4 deficiency (~60%). About 1,000 cases reported worldwide. Similar incidence in males and females.
5. PathophysiologyBH4 deficiency → reduced PAH activity (Phe accumulation) + reduced tyrosine hydroxylase (TH) and tryptophan hydroxylase (TPH) activity → decreased synthesis of dopamine, norepinephrine, and serotonin → dual neurotoxicity (Phe toxicity + neurotransmitter deficiency). In DHPR deficiency, BH4 cannot be regenerated → accompanied by additional folate metabolism abnormalities.
6. SymptomsLow-phenylalanine diet alone insufficient for symptom control — progressive neurological symptoms: dystonia, dysphagia, seizures, autonomic dysfunction (hypersalivation, temperature instability, abnormal sweating), intellectual disability, irritability. Most severe in the 'malignant hyperphenylalaninemia' phenotype.
7. SignsElevated blood Phe (mild to moderate; 500–1,200 μmol/L in some cases). Abnormal urinary pterin profile (type-specific pattern). Decreased cerebrospinal fluid (CSF) neurotransmitter metabolites (HVA, 5-HIAA). EEG abnormalities. Dopa-responsive dystonia (Segawa form).
8. ScreeningNewborn screening (MS/MS): initial detection by elevated blood Phe → differentiation of BH4 deficiency by urinary pterin profile (HPLC or MS/MS) → measurement of erythrocyte DHPR enzyme activity. Phe may be normal in the dominant GTPCH form (Segawa) → separate testing when clinically suspected.
9. DiagnosisPlasma amino acids (Phe, Tyr). Urinary pterin profile (neopterin, biopterin). Erythrocyte DHPR activity. CSF neurotransmitter metabolites (HVA, 5-HIAA, MHPG, biopterin). Gene panel NGS (GCH1, PTS, QDPR, PCBD1, SPR). BH4 loading test.
10. TreatmentSapropterin (BH4) supplementation — control of blood Phe. Neurotransmitter precursor supplementation: L-DOPA/carbidopa (dopamine pathway supplementation), 5-hydroxytryptophan (5-HTP, serotonin pathway). Folinic acid (cerebral folate supplementation in DHPR deficiency). Low-phenylalanine diet (adjunctive). Neurological complications can be prevented with early treatment.
11. PrognosisNeurodevelopment improves markedly with early diagnosis and neurotransmitter precursor treatment. Irreversible neurological damage if treatment is delayed. DHPR deficiency tends to have a poorer prognosis than PTPS and GTPCH deficiency. There are cases of normal intellectual development when dystonia and seizures are well controlled with appropriate neurotransmitter treatment.
12. PreventionPrimary: genetic counseling, family genetic testing, prenatal diagnosis. Secondary: early differentiation of BH4 deficiency after newborn screening (pterin testing + DHPR measurement), immediate initiation of neurotransmitter treatment in the neonatal period. Tertiary: CSF monitoring, regular neurodevelopmental assessment, optimization of neurotransmitter treatment doses, school and educational support.
13. ReferencesBlau N et al. Consensus guideline for the diagnosis and treatment of tetrahydrobiopterin (BH4) deficiencies. Orphanet J Rare Dis. 2020. and 9 other papers

1. History

The history of other hyperphenylalaninemias (E70.1), i.e., tetrahydrobiopterin (BH4) deficiency, begins in the 1970s when newborn screening for phenylketonuria (PKU) became widespread. Around 1973–1974, it was reported that some newborns suspected of PKU who had started a low-phenylalanine diet developed progressive neurological symptoms (seizures, hypotonia, developmental regression) despite dietary treatment. In these infants, PAH enzyme activity was normal or only mildly reduced. In 1974, Smith et al. described this as "malignant hyperphenylalaninaemia", which was the first clear proposal that a cause different from simple PAH deficiency existed.

From the mid-1970s, researchers focused on the biosynthetic and regeneration pathways of tetrahydrobiopterin (BH4), a cofactor essential for the phenylalanine hydroxylation reaction. In 1975, Milstein, Zackai, and colleagues showed through urinary pterin analysis that abnormal BH4 biosynthesis was the cause in some infants positive on newborn screening. 6-Pyruvoyl-tetrahydropterin synthase (PTPS) deficiency was identified as an independent cause in 1976, and dihydropteridine reductase (DHPR) deficiency in 1977.

In the 1980s, additional enzyme deficiencies of the BH4 metabolic pathway were identified, including GTP cyclohydrolase I (GTPCH) deficiency, pterin-4a-carbinolamine dehydratase (PCD) deficiency, and sepiapterin reductase (SR) deficiency. In particular, the association of dopa-responsive dystonia (DRD), described by Segawa et al. in 1984, with variants in the GTPCH gene (GCH1) was established by Ichinose et al. in 1994, highlighting that BH4 deficiency is a key cause of neurotransmitter disorders beyond simple HPA.

In terms of molecular genetics, the relevant genes were cloned from the 1980s to the 2000s: GCH1 (1994), PTS (1994), QDPR (1992), PCBD1 (2000s), SPR (2003). The international BH4 deficiency database (BIODEF, led by Blau N) was established, enabling worldwide case registration and research collaboration. In 2020, an international expert group led by Blau N published international consensus guidelines for the diagnosis and treatment of BH4 deficiency in Orphanet Journal of Rare Diseases, setting a clinical standard (PMID: 32503652).

In Korea, from the late 1980s some infants suspected of PKU after positive newborn screening began to be identified as having BH4 deficiency, and a system is now established in which pterin testing and DHPR measurement are always performed together when newborn screening is positive in order to differentiate BH4 deficiency. In East Asia, PTPS deficiency in particular is reported as the most common form of BH4 deficiency.


2. Causes

Other hyperphenylalaninemias (BH4 deficiency) result from inherited deficiency of enzymes involved in the biosynthesis or regeneration of tetrahydrobiopterin (BH4). BH4 is an essential cofactor of phenylalanine hydroxylase (PAH), tyrosine hydroxylase (TH), and tryptophan hydroxylase (TPH). Therefore, in addition to phenylalanine accumulation due to simple reduction of PAH function, BH4 deficiency causes a dual pathology of impaired synthesis of catecholamines (dopamine, norepinephrine, epinephrine) and serotonin.

BH4 is synthesized from guanosine triphosphate (GTP) through three enzymatic steps. Enzyme deficiency at each step causes an independent subtype of BH4 deficiency.

BH4 is also a cofactor of nitric oxide synthase (NOS), so BH4 deficiency may also be partly accompanied by vascular dysfunction. Each enzyme deficiency subtype shows a phenotypic spectrum ranging from mild to severe depending on the type of gene variant and residual enzyme activity.


3. Genetics

The inheritance pattern of BH4 deficiency differs by subtype, but most subtypes other than SR deficiency follow autosomal recessive inheritance. However, GTPCH deficiency has two inheritance forms: an autosomal recessive form (causing HPA, OMIM #233910) and an autosomal dominant form (Segawa disease/dopa-responsive dystonia, OMIM #128230).

The genes and chromosomal locations of each subtype are as follows. GCH1 (GTPCH): 14q22.1, 6 exons, OMIM *600225. PTS (PTPS): 11q23.1, 6 exons, OMIM *261640. QDPR (DHPR): 4p15.32, 7 exons, OMIM *612676. PCBD1 (PCD): 10q22.1, OMIM *126090. SPR (SR): 2p13.2, OMIM *182125.

PTS gene variants are the most frequently found in Asian patients with BH4 deficiency. More than 100 PTS variants have been reported in the international BIODEF database and the literature, and certain variants reported in Korean, Chinese, and Japanese patients (e.g., p.Asn52Ser, p.Pro87Leu, p.Thr67Met) have been identified as common East Asian variants. In the GCH1 gene, de novo mutations have also been reported in the dominant form (Segawa disease).

In terms of genetic counseling, parents in the recessive subtypes are carriers, and the recurrence risk for children is 25%. In the dominant form (Segawa), it is transmitted from an affected parent with a 50% probability. Phenotypic variability is large in PTPS deficiency, and a mild HPA form and a severe neurological form can coexist even with the same variant. This is explained by environmental factors, residual enzyme activity, and the complexity of gene variants.

SR deficiency requires particular attention, because in this subtype blood Phe is normal and it may not be detected by newborn screening. It is diagnosed after neurological symptoms (dystonia, oculomotor abnormalities, developmental delay) appear after birth, through cerebrospinal fluid neurotransmitter metabolite analysis and genetic testing.


4. General epidemiology

BH4 deficiency is a rare disease accounting for about 1–3% of all hyperphenylalaninemia (HPA). Worldwide, the proportion of BH4 deficiency among positive newborn screening results varies by region, but the overall incidence is estimated at about 1:1,000,000–1:2,000,000. More than about 1,000 cases are registered in the international BIODEF database as of the 2020s.

The distribution by subtype differs markedly by region. In Europe and the Middle East, PTPS deficiency and DHPR deficiency are the most common. In East Asia (Korea, China, Taiwan, Japan), PTPS deficiency is the most common form, accounting for about 60–80% of BH4 deficiency. In Chinese data (2006–2010), PTPS deficiency accounted for about 1.2% of newborns positive for HPA (2–3% of all HPA). In Korea, PTPS deficiency also accounts for most BH4 deficiency, and DHPR deficiency and GTPCH deficiency are rarely reported. Sex distribution differs by subtype, but overall equal incidence in males and females is reported.

SR deficiency is very rare, at the level of a few dozen cases worldwide, and because there is no HPA it is easily missed by newborn screening, so its actual prevalence may be underestimated. PCD deficiency is a cause of mild HPA; some literature reports that it accounts for a considerable proportion of positive newborn screening results, but its clinical significance is minor.

In Korea, an established newborn screening system enables early detection of BH4 deficiency, but because its incidence is low, intensive management at specialized metabolic disease centers is required. According to rare disease statistics, the number of registered patients in Korea is only small, and they are covered by Special Copayment Reduction V117.


5. Pathophysiology

The pathophysiology of BH4 deficiency causes nervous system damage through a dual mechanism that is more complex than PKU (isolated PAH deficiency). The first mechanism is phenylalanine accumulation: because BH4 is a cofactor of PAH, PAH activity is reduced in BH4 deficiency and blood Phe rises. This causes competition for large neutral amino acid (LNAA) transport into the brain, suppressing brain uptake of other neurologically important amino acids.

The second and more important mechanism is impaired neurotransmitter synthesis. BH4 is a cofactor not only of PAH but also of tyrosine hydroxylase (TH) and tryptophan hydroxylase (TPH). TH converts tyrosine to L-DOPA, catalyzing the first rate-limiting step of the dopamine synthesis pathway, and TPH converts tryptophan to 5-hydroxytryptophan (5-HTP), initiating serotonin synthesis. In BH4 deficiency, reduced TH and TPH activity → synthesis of dopamine (dopaminergic neurotransmission), norepinephrine, and serotonin is markedly decreased. Deficiency of these three neurotransmitters is not corrected by a low-phenylalanine diet alone, which is why progressive neurological symptoms appear despite dietary therapy.

In DHPR deficiency, an additional mechanism operates. Quinonoid dihydrobiopterin (qBH2) cannot be reduced to BH4, so BH4 cannot be regenerated, and in this process metabolism of 5-methyltetrahydrofolate (5-MTHF) is also affected, resulting in cerebral folate deficiency. Cerebral folate deficiency causes additional damage to myelination and neurotransmitter metabolism. This is one of the reasons why DHPR deficiency has a poorer prognosis than other BH4 deficiency subtypes.

In SR deficiency, blood Phe is normal or only mildly elevated, but a defect in the final step of BH4 synthesis reduces the BH4 supply, leading to decreased TH and TPH activity → reduced dopamine and serotonin synthesis. Clinically, only symptoms of neurotransmitter deficiency appear without HPA, so it may not be detected by newborn screening.


6. Symptoms

Symptoms of BH4 deficiency vary by subtype and severity, but neurological symptoms due to neurotransmitter deficiency commonly predominate, and the key difference from PKU is that symptoms are not controlled by a low-phenylalanine diet alone.

Neurological symptoms: progressive hypotonia, dystonia, dyskinesia, and rigidity appear. Dysphagia and sialorrhoea are commonly accompanying. Seizures are frequent, especially in DHPR deficiency and severe forms of GTPCH deficiency. Developmental regression may appear progressively.

Autonomic abnormalities: impaired thermoregulation (hyperthermia or hypothermia), hypersalivation, abnormal sweating, irregular breathing, etc. occur due to dopamine and norepinephrine deficiency. These are particularly prominent in PTPS deficiency and DHPR deficiency.

Cognitive and behavioral abnormalities: intellectual disability (if not treated early), irritability, and sleep disturbances may occur. With appropriate treatment, cognitive impairment can be prevented or minimized.

Segawa disease (dominant GTPCH): characterized by dopa-responsive dystonia (DRD), usually starting with lower-limb dystonia in childhood to adolescence. Symptoms show diurnal fluctuation, being mild in the morning and worsening in the afternoon and evening. Responds dramatically to low-dose L-DOPA.

PCD deficiency: only mild HPA and mild neurological symptoms appear, and some cases improve spontaneously without treatment. It is also called 'benign hyperphenylalaninemia (benign HPA)'.


7. Signs

Objective signs of BH4 deficiency are confirmed by biochemical testing, neurological examination, and brain imaging.

Elevated blood phenylalanine: varies by subtype from mild (PCD, SR) to moderate (PTPS, DHPR, recessive GTPCH). Often lower than in classic PKU (≥1,200 μmol/L), but there are exceptions.

Abnormal urinary pterin profile: each subtype shows a specific pattern. Recessive GTPCH deficiency: both neopterin and biopterin decreased. PTPS deficiency: neopterin markedly increased, biopterin decreased (biopterin ratio <20%). DHPR deficiency: biopterin markedly increased, neopterin increased. PCD deficiency: biopterin increased, appearance of primapterin.

Reduced erythrocyte DHPR enzyme activity: the key marker for diagnosing DHPR deficiency. Can be measured in dried blood spots (DBS) or fresh blood.

Decreased cerebrospinal fluid (CSF) neurotransmitter metabolites: homovanillic acid (HVA, a dopamine metabolite), 5-hydroxyindoleacetic acid (5-HIAA, a serotonin metabolite), and 3-methoxy-4-hydroxyphenylglycol (MHPG, a norepinephrine metabolite) are markedly decreased. CSF biopterin is also decreased. This test is also essential for monitoring neurotransmitter treatment.

Brain MRI abnormalities: in severe cases, basal ganglia signal abnormalities, white matter changes, brain atrophy, etc. may appear. Calcium deposition may be observed in DHPR deficiency.


8. Screening

Screening for BH4 deficiency proceeds through a two-step differentiation process linked to PKU newborn screening.

Step 1: neonatal blood Phe measurement (MS/MS): blood Phe is measured by MS/MS in dried blood spots at 48–72 hours after birth. Blood Phe >120 μmol/L is judged positive for hyperphenylalaninemia and leads to confirmatory testing. In SR deficiency, Phe may be normal, so it may not be detected at this step.

Step 2: differential testing for BH4 deficiency: after HPA is confirmed, urinary pterin profile (measurement of neopterin, biopterin, primapterin, total biopterin) and erythrocyte DHPR enzyme activity must be performed in all affected infants. These two tests can differentiate most subtypes of BH4 deficiency. When SR deficiency is suspected, measurement of CSF neurotransmitter metabolites and CSF biopterin is needed.

BH4 loading test (optional): changes in blood Phe are observed after oral administration of sapropterin 20 mg/kg. Used as an aid in differentiating BH4-responsive HPA (mild forms of PAH deficiency or some BH4 deficiencies).

Family screening and prenatal diagnosis: after definitive diagnosis, genetic testing of carrier parents and prenatal genetic diagnosis in future pregnancies are possible. The causative gene variant is identified by molecular genetic testing (NGS panel: including GCH1, PTS, QDPR, PCBD1, SPR).


9. Diagnosis

Definitive diagnosis of BH4 deficiency is made by integrating urinary pterin analysis, enzyme activity measurement, CSF neurotransmitter analysis, and molecular genetic testing.

Quantitative plasma amino acid analysis: measurement of blood Phe and Tyr. The degree of Phe elevation differs by subtype, and Phe may be normal in SR deficiency.

Urinary pterin profile (HPLC or MS/MS): quantitative analysis of neopterin, biopterin, primapterin, 7-biopterin, and monapterin. Diagnosis is guided by the specific pattern of each subtype:

Measurement of erythrocyte DHPR enzyme activity: essential for confirming DHPR deficiency. Measured in DBS or fresh blood erythrocytes.

CSF neurotransmitter analysis: quantification of homovanillic acid (HVA), 5-HIAA, MHPG, and CSF pterins (biopterin, neopterin). Provides the basis for treatment monitoring and L-DOPA/5-HTP dose adjustment. Essential for confirming SR deficiency.

Molecular genetic testing (NGS panel): GCH1, PTS, QDPR, PCBD1, SPR gene panel testing. Identification of pathogenic variants enables definitive diagnosis and family testing.

Brain MRI: assessment for basal ganglia abnormalities, white matter lesions, and brain atrophy. Examination for basal ganglia calcification in DHPR deficiency.


10. Treatment

Treatment of BH4 deficiency is more complex than PKU treatment in that two key goals—control of blood Phe and neurotransmitter supplementation—must be achieved simultaneously.

Sapropterin (BH4) supplementation: in most PTPS deficiency and GTPCH deficiency, exogenous BH4 supply enhances PAH activity and lowers blood Phe. Sapropterin dihydrochloride (2–20 mg/kg/day) is given orally. BH4 treatment can relax or eliminate dietary restriction.

Neurotransmitter precursor supplementation — key treatment: L-DOPA/carbidopa (carbidopa inhibits peripheral DOPA decarboxylation) is given to supplement the dopamine pathway. 5-Hydroxytryptophan (5-HTP) is given to supplement the serotonin pathway. Combined administration of the two precursors is the standard treatment. Doses are adjusted based on CSF neurotransmitter levels and clinical response. Neurodevelopment can improve markedly when treatment is started early at sufficient doses.

Folate supplementation (specific to DHPR deficiency): in DHPR deficiency, high-dose folate or folinic acid is given to correct cerebral folate deficiency.

Low-phenylalanine diet (adjunctive): used as an adjunct for controlling blood Phe, but in BH4 deficiency diet alone without neurotransmitter supplementation is insufficient.

Symptom control: anticonvulsants for seizures. For dystonia, L-DOPA dose adjustment and botulinum toxin injection (for focal dystonia). In Segawa disease, dramatic symptom improvement is possible with low-dose L-DOPA alone.


11. Prognosis

The prognosis of BH4 deficiency varies greatly depending on subtype, timing of diagnosis, timing of treatment initiation, and adequacy of treatment. Overall, early diagnosis and appropriate neurotransmitter treatment are the most important determinants of prognosis.

In patients with PTPS deficiency or GTPCH deficiency detected early through newborn screening and started on L-DOPA/5-HTP and BH4 treatment from the neonatal period, normal or near-normal neurodevelopment is reported. In contrast, when treatment is delayed, irreversible neurological damage remains, and intellectual disability, dystonia, seizures, etc. persist.

DHPR deficiency tends to have a poorer prognosis than the other subtypes. Because additional damage from cerebral folate deficiency occurs, folate supplementation must also be started early in addition to BH4 and neurotransmitter treatment. Despite treatment, brain atrophy, basal ganglia calcification, and intellectual disability may progress in some patients.

SR deficiency is not detected by newborn screening, so treatment is often delayed, and the prognosis tends to be poor. With early detection and treatment, improvement in motor function is possible, but complete recovery of cognitive function is uncertain.

Segawa disease (dominant GTPCH) responds dramatically to low-dose L-DOPA and is a subtype with a good prognosis, allowing a normal life with appropriate treatment. However, if left untreated, it leads to progressive disability.


12. Prevention

Prevention strategies for BH4 deficiency focus on early detection and prompt initiation of treatment.

Primary prevention: genetic counseling and carrier testing for families of confirmed patients. Affected fetuses can be detected early through prenatal genetic diagnosis (chorionic villus sampling or amniocentesis) and preimplantation genetic testing (PGT-M).

Secondary prevention (early detection): a standardized differentiation protocol is essential in which urinary pterin profile and DHPR enzyme activity are performed immediately in all HPA infants when newborn screening (MS/MS blood Phe measurement) is positive. For subtypes with normal Phe, such as SR deficiency, a system for prompt additional testing when neurological symptoms such as dystonia appear is needed. Starting neurotransmitter precursor treatment as soon as the diagnosis is confirmed in the neonatal period is the key to preventing neurological damage.

Tertiary prevention (minimizing complications): optimization of treatment doses through regular CSF neurotransmitter monitoring (every 3–6 months early in treatment, at least once a year after stabilization). Brain MRI follow-up, neurodevelopmental assessment (at least once a year), EEG (patients with seizures). Education and psychological support for families and patients. During the growth period, whether to continue dietary and drug treatment and the doses are regularly reassessed.


13. References

  1. Blau N, Hennermann JB, Langenbeck U, Lichter-Konecki U. Diagnosis, classification, and genetics of phenylketonuria and tetrahydrobiopterin (BH4) deficiencies. Mol Genet Metab. 2011;104(Suppl):S2-S9. DOI: 10.1016/j.ymgme.2011.08.017
  2. Blau N, Shen N, Carducci C. Molecular genetics and diagnosis of phenylketonuria: state of the art. Expert Rev Mol Diagn. 2014;14(6):655-671. DOI: 10.1586/14737159.2014.923760
  3. Opladen T, López-Laso E, Cortès-Saladelafont E, et al. Consensus guideline for the diagnosis and treatment of tetrahydrobiopterin (BH4) deficiencies. Orphanet J Rare Dis. 2020;15(1):126. DOI: 10.1186/s13023-020-01379-8
  4. Thöny B, Auerbach G, Blau N. Tetrahydrobiopterin biosynthesis, regeneration and functions. Biochem J. 2000;347(1):1-16. DOI: 10.1042/0264-6021:3470001
  5. Segawa M, Nomura Y, Nishiyama N. Autosomal dominant guanosine triphosphate cyclohydrolase I deficiency (Segawa disease). Ann Neurol. 2003;54(Suppl 6):S32-S45. DOI: 10.1002/ana.10630
  6. Huang XW, Yang ZG, Liang CL, et al. Distribution of 6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency in China: The first data for newborn screening in 25 years. Orphanet J Rare Dis. 2022;17(1):95. DOI: 10.1186/s13023-022-02243-3
  7. Ferrè S, de Baaij JH, Ferreira P, et al. Mutations in PCBD1 cause hypomagnesemia and renal magnesium wasting. J Am Soc Nephrol. 2014;25(3):574-586. DOI: 10.1681/ASN.2013040337
  8. Bonafé L, Thöny B, Penzien JM, et al. Mutations in the sepiapterin reductase gene cause a novel tetrahydrobiopterin-dependent monoamine-neurotransmitter deficiency without hyperphenylalaninemia. Am J Hum Genet. 2001;69(2):269-277. DOI: 10.1086/321970
  9. Park CS, Lee DH, Kim GH, et al. Molecular and biochemical characterization of hyperphenylalaninemia in Korean patients. J Hum Genet. 2010;55(5):322-326. DOI: 10.1038/jhg.2010.23
  10. Leuzzi V, Carducci C, Cardona F, et al. The phenotypical spectrum of nonphenylketonuric hyperphenylalaninemia including a new mutation in the phenylalanine hydroxylase gene. J Neurol Neurosurg Psychiatry. 2000;68(1):70-74. DOI: 10.1136/jnnp.68.1.70